NCT05955014 Data Collection Protocol for Patients With Von Hippel Lindau Disease
| NCT ID | NCT05955014 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Von Hippel Lindau Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 125 participants |
| Start Date | 2023-08-24 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 125 participants in total. It began in 2023-08-24 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.
Eligibility Criteria
Inclusion Criteria: * Presence of genetic confirmation or clinical criteria consistent with vHL disease. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Contact & Investigator
Eric Jonasch, MD
PRINCIPAL INVESTIGATOR
ejonasch@mdanderson.org
Frequently Asked Questions
Who can join the NCT05955014 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Von Hippel Lindau Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05955014 currently recruiting?
Yes, NCT05955014 is actively recruiting participants. Contact the research team at ejonasch@mdanderson.org for enrollment information.
Where is the NCT05955014 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT05955014 clinical trial?
NCT05955014 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Eric Jonasch, MD at ejonasch@mdanderson.org. The trial plans to enroll 125 participants.